On this page you will find links to key resources and tools to enable robust trial designs during the COVID-19 outbreak, as well as the latest information regarding ongoing trials.
There are many questions surrounding COVID-19 trials that may vary across different settings. Are you considering conducting a trial? If so, then please let us know what you have planned and if you need any support. Are you looking for groups to collaborate with? Do you want to let others know you would like to be a site in a trial they are planning?
We want to support any team wanting to run a high-quality trial in different settings and especially in LMICs. We can help coordinate discussions and support your plans. We can also set up a forum for developing ideas and asking questions. Please get in touch and get involved!
Solidarity Therapeutics Trial produces conclusive evidence on the effectiveness of repurposed drugs for COVID-19 in record time
In just six months, the world’s largest randomized control trial on COVID-19 therapeutics has generated conclusive evidence on the effectiveness of repurposed drugs for the treatment of COVID-19. The full article can be accessed here.
NAVIGATE INTERVENTION TRIALS BELOW:
What Support is Available?
The European Medicines Agency (EMA) encourages developers of potential vaccines or treatments for novel coronavirus infection to contact EMA as soon as possible to discuss their strategy for evidence-generation, by emailing 2019-ncov@ema.europa.eu. The EMA can also provide medicine developers with scientific advice on the most appropriate way to generate robust evidence on a medicine's benefits and risks. Scientific advice is free of charge and can be fast-tracked for potential novel coronavirus treatments or vaccines.
In response to the emergence of COVID-19, the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) has developed a portfolio of resources to accelerate outbreak research and response.
Fundação Oswaldo Cruz (Fiocruz) has created a resource area highlighting important sources of information about the pandemic, to facilitate the circulation of knowledge and help the entire scientific community to keep abreast of the latest news about the disease.